GNFTF Stock Chart & Stats
$11.05
$0.10(2.91%)
At close: 4:00 PM EST
$11.05
$0.10(2.91%)
Day’s Range― - ―
52-Week Range$3.28 - $11.10
Previous CloseN/A
Volume2.00K
Average Volume (3M)0.00
Market Cap
$781.31M
Enterprise Value$550.39M
Total Cash (Recent Filing)$101.09M
Total Debt (Recent Filing)$150.69M
Price to Earnings (P/E)―
Beta0.22
Next Earnings
Sep 29, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.72
Shares Outstanding50,096,220
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-11.11
Price to Sales (P/S)4.01
P/FCF Ratio-9.84
Enterprise Value/Market Cap0.70
Enterprise Value/Revenue8.16
Enterprise Value/Gross Profit31.34
Enterprise Value/Ebitda-90.91
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.14
Revenue Forecast (FY)$100.52M
Bulls Say, Bears Say
Bulls Say
Revenue Rebound (2025)A ~45% top-line rebound in 2025 indicates the company can materially grow sales, which supports long-term commercial viability. Sustained revenue recovery strengthens pricing leverage, partner negotiations and the potential to fund R&D or diagnostics rollouts without sole reliance on external capital.
Diversified Biotech Revenue ModelA mixed revenue model—diagnostic product sales plus licensing/collaboration payments—provides multiple durable funding channels. Upfronts/milestones and royalties can offset R&D cyclicality and reduce reliance on equity raises if executed, improving long-term resilience in biotech funding cycles.
Demonstrated Positive Cash YearsPrior years of positive operating and free cash flow show the business can achieve self-funded operations under the right conditions. This operational upside demonstrates potential for sustainable cash generation if revenue growth and cost discipline are maintained, improving funding optionality.
Bears Say
Balance-sheet Stress / Negative EquityThe shift to negative shareholders' equity and higher debt materially reduces financial flexibility and increases insolvency risk. Over mid-term horizons this can raise funding costs, force dilutive financing or constrain strategic initiatives, limiting the company's ability to execute its clinical and commercial plans.
Return To Large Operating And Net LossesReversion to sizable operating and net losses undermines profitability durability and heightens dependence on external funding. Persistent losses can impede scale-up of diagnostics, slow commercialization, and reduce bargaining power with partners, pressuring long-term strategic execution.
Inconsistent Cash Generation And Renewed Cash BurnRecurring negative operating and free cash flow increases the likelihood of near-term funding needs and dilutive financing. Structural cash volatility limits runway, forces prioritization of projects, and can hinder sustained investment in commercialization and late-stage development over the coming months.
Genfit News
GNFTF FAQ
What was Genfit SA’s price range in the past 12 months?
Genfit SA lowest stock price was $3.28 and its highest was $11.10 in the past 12 months.
What is Genfit SA’s market cap?
Genfit SA’s market cap is $781.31M.
When is Genfit SA’s upcoming earnings report date?
Genfit SA’s upcoming earnings report date is Sep 29, 2026 which is in 77 days.
How were Genfit SA’s earnings last quarter?
Genfit SA released its earnings results on Apr 02, 2026. The company reported -$1.738 earnings per share for the quarter, missing the consensus estimate of -$0.034 by -$1.704.
Is Genfit SA overvalued?
According to Wall Street analysts Genfit SA’s price is currently Overvalued.
Does Genfit SA pay dividends?
Genfit SA does not currently pay dividends.
What is Genfit SA’s EPS estimate?
Genfit SA’s EPS estimate is -0.02.
How many shares outstanding does Genfit SA have?
Genfit SA has 50,096,220 shares outstanding.
What happened to Genfit SA’s price movement after its last earnings report?
Genfit SA reported an EPS of -$1.738 in its last earnings report, missing expectations of -$0.034. Following the earnings report the stock price went up 0.806%.
Which hedge fund is a major shareholder of Genfit SA?
Currently, no hedge funds are holding shares in GNFTF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Genfit SA
Genfit S.A. operates as a biopharmaceutical enterprise, concentrating its efforts on discovering and developing both therapeutic candidates and diagnostic solutions for metabolic and liver-related ailments. Its current pipeline includes Elafibranor, which is progressing through Phase 3 clinical trials for the treatment of primary biliary cholangitis (PBC). The firm is additionally engaged in advancing the NIS4 technology, designed for the accurate diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. Other investigational treatments comprise GNS561, currently in Phase 1b/2 trials for cholangiocarcinoma (CCA), and Nitazoxanide, undergoing Phase 1 evaluation for acute-on-chronic liver failure. Genfit has established key partnerships, notably a licensing agreement with Labcorp for the commercialization of NASHnext, a molecular diagnostic test leveraging blood samples. Furthermore, it collaborates with Genoscience Pharma on the development and market launch of the experimental CCA therapy, GNS561. Established in 1999, Genfit S.A. maintains its headquarters in Loos, France.
Technical Analysis
Ownership Overview
―
Insiders
0.02% Mutual Funds
― Other Institutional Investors
99.98% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---